Figure 3.
Therapeutic choices before (A) and after (B) the beginning of dostarlimab expanded access program (EAP). ICI, immune checkpoint inhibitor other than dostarlimab.
Therapeutic choices before (A) and after (B) the beginning of dostarlimab expanded access program (EAP). ICI, immune checkpoint inhibitor other than dostarlimab.